Join the Next Phase of DocSWISS-AI
DocSWISS-AI — our radiation-tolerant edge-AI vital signs patch at TRL 4 — is lab-validated and ready for pilots. As the first CRO with space-validated evidence targeting a fast-track EMA pathway, it delivers the decision cockpit: real-time predictive alerts (target ≥95% accuracy) + unique retraction strategy to eliminate ongoing risk (QoL/performance/safety impact). This avoids massive follow-up costs from wrong decisions — unnecessary interventions, liability claims, lost productivity, and even preventable deaths — while costing clients only ~10% of the avoided expenses.
Market Opportunity
Global medical wearables market: €18–20B (2025) → €57B+ by 2030 (CAGR ~17%).
Cross-sector TAM
• Healthcare: €1.3–7B
• Defense & Security: €4.7B
• Space: €1.5–1.7B
• Industrial Safety: €2–5B
• Aviation & Mass Events: Included in defense/aviation
• Financial/Insurance & Wellness: €12–14B
Business Model & Traction
• B2B2C: Device (€200–400) + subscription (€15–30/mo) + brokerage fees via EuDiPPA.
• Realistic 5-year revenue: €450–500M (base case).
• Break-even: Year 2–3.
• Exit target: Acquisition by medtech/defense corporation (2029–2032).
• Current stage: TRL 4 (lab-validated) → seeking pilots (TRL 5–6), grants (EU4Health, Horizon, EIC), and seed/bridge funding (€8–12M total).
Why Invest Now?
• Unique differentiator: Retraction strategy eliminates risk exposure — first in class for sovereign, patient-first edge-AI.
• Space-validated fast-track EMA: Dual-use resilience (radiation >100–300 krad) from space analogs → clinical approval advantage.
• Lean startup model: All key team members part-time domain experts (high-caliber, low-cost) — scalable to full-time.
• Strong foundation: MoU/NDA signed with EuDiPPA, Digital Health Europe (Partnering 4 Human Health & Performance, Improving Outcomes & Impacts), and Prof. C.J. Schilt (VUB – grant/university coordinator).
• High cross-sector potential: Defense, space, aviation, healthcare, industrial, insurance/wellness — €10B+ combined TAM.
Investment Ask
• Seed/bridge funding: €2–5M equity/debt (post-grant traction).
• Total 2026–2028: €8–12M (70–80% grants + equity).
• Use of funds: Prototype scaling, pilots, EMA dossier, team growth.
• Exit potential: Medtech/defense acquisition (2029–2032).
Team & Expertise (brief summary)
Lean structure with part-time experts
• Dr. Johannes Petrus Maria (John) Wubbe – President & Founder (vision/strategy).
• Menno Nijdam – COO (operations/milestones).
• Guilherme (Gonçalo) Monteiro Ferreira – Market Access & Pharma (EMA/payer strategy).
• Erwin Wolff – CTO (Rust/ICT stack).
• Prof. C.J. Schilt (VUB) – Grant/University Coordinator (ethics/governance).
Next Steps for Investors
Download the Investor Deck or contact us to discuss:
• Valuation & terms.
• Grant pipeline leverage (EU4Health Jan 2026, Horizon Apr 2026, EIC May 2026).
• Equity in Swiss AG structure.
Contact
Email: john.wubbe@doc.swiss
Phone: +41 79 946 38 43